# OnCo record nct06362252 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06362252/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06362252", "NCT06362252" ;
  schema:name "A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-"@en ;
  schema:alternateName "IDeate-Lung03"@en ;
  schema:description "A phase 1/2 trial of Ifinatamab deruxtecan, Atezolizumab, Carboplatin in small-cell lung cancer, run by Daiichi Sankyo, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06362252/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06362252> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2024-07-22" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/extensive-stage-sclc/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/ifinatamab-deruxtecan/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/daiichi-sankyo/> .